# Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer

> **NCT01279291** · PHASE1 · TERMINATED · sponsor: **Kyowa Kirin Co., Ltd.** · enrollment: 22 (actual)

## Conditions studied

- Neoplasms
- Ovarian Neoplasms
- Fallopian Tube Neoplasms
- Primary Peritoneal Neoplasm

## Interventions

- **BIOLOGICAL:** KHK2866
- **DRUG:** Gemcitabine and Carboplatin
- **DRUG:** paclitaxel
- **DRUG:** pegylated liposomal doxorubicin

## Key facts

- **NCT ID:** NCT01279291
- **Lead sponsor:** Kyowa Kirin Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-01
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** The study was stopped due to the inability to determine an acceptable dose with the potential for further study
- **Last updated:** 2024-04-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01279291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01279291, "Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01279291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*